The company is Zeltia. Zeltia has a BioPharma called Pharmamar, who manufacture Yondelis for ovarius cancer.

In USA J&J is going to comercialize the product. We are waitng for the approval. Zeltia's value is 3,35.

This is our hot stock.

Sorry me, my english is very poor. But i hope that you understand me.

Edit:

I am very glad, because you have the FDA Calendar FREE. Really thanks you. I was looking for this since 1 month, i was ready to buy it from BioMedicine.

I would like to share with you my information. The Spanish product approval on FDA is between 19-23 Sept. And the nex week we are waiting for the results of EMEA, for comercialize/marketing this product (YONDELIS) in all Europe.

We say that we are sure that EMEA approve this. But we are not so positive with USA bcuz Johnson & Johnson have politics problems with FDA.

Sorry for my poor english. And thanks you!